AOD-9604: Two Research Questions, Different Evidence
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

AOD-9604 has been studied for two very different questions: body weight and cartilage. Following the evidence means keeping those research programs separate. It was developed from part of the growth-hormone sequence. An obesity trial did not show a significant weight-loss advantage over placebo, and that development program was stopped. Later cartilage research included an experimentally induced knee-arthritis model in rabbits. Tissue findings in that model cannot establish that AOD-9604 repairs human joints. A new research angle does not erase an earlier trial result. Each proposed use needs convincing human benefit, safety data, and evaluation of the actual formulation.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] FDA December 2024 briefing: evaluation of AOD-9604-related substances
https://www.fda.gov/media/183584/download
US regulatory evidence review

[2] Effect of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model (2015)
https://pubmed.ncbi.nlm.nih.gov/26275694/
Primary animal experiment

EVIDENCE LIMITATIONS
FDA reports 536 enrolled and 502 randomized in the major study; avoid conflating those counts.
The rabbit intervention and outcome cannot be generalized to human arthritis or other routes.
No fat-loss, cartilage-regrowth, or growth-hormone-equivalence promise is made.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1651454239972016/